Erikstein B, Nesland J M, Ottestad L, Lund E, Johannessen J V
General Department, Norwegian Radium Hospital, Oslo.
Histol Histopathol. 1988 Jan;3(1):97-102.
Ninety-eight patients treated for breast carcinomas were followed from 54 to 75 months after primary diagnosis. All had undergone a modified radical mastectomy with removal of axillary lymph nodes. 36 breast carcinomas were NSE-positive and 62 were negative. NSE-positive tumours were significantly more frequently estrogen receptor-positive than the NSE-negative tumours, and the estrogen receptor values were higher in the NSE-positive groups. Patients with NSE-positive tumours and patients with NSE-negative tumours did not differ with regard to presence of lymph node metastases at the time of primary surgery. However, the study showed that patients with NSE-positive tumours had a tendency towards more lymph node metastases after primary surgical intervention, but a better outcome than patients with NSE-negative tumours and metastases. This study, with a 5-year follow up, failed to demonstrate any major prognostic significance of immunostaining for NSE.
对98例乳腺癌患者在初次诊断后进行了54至75个月的随访。所有患者均接受了改良根治性乳房切除术并清扫了腋窝淋巴结。36例乳腺癌NSE呈阳性,62例呈阴性。NSE阳性肿瘤的雌激素受体阳性率显著高于NSE阴性肿瘤,且NSE阳性组的雌激素受体值更高。NSE阳性肿瘤患者和NSE阴性肿瘤患者在初次手术时的淋巴结转移情况无差异。然而,研究表明,NSE阳性肿瘤患者在初次手术干预后有更多淋巴结转移的倾向,但预后比有转移的NSE阴性肿瘤患者更好。这项为期5年随访的研究未能证明NSE免疫染色有任何主要的预后意义。